Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

In vivo response monitoring of treatment with the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in metastatic colorectal cancer: a single centre phase II study.

Next Previous
Trial Profile

In vivo response monitoring of treatment with the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in metastatic colorectal cancer: a single centre phase II study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms REMOTUX

Most Recent Events

  • 02 Jul 2018 Primary endpoint has been met. (predictive significance of DeltaSUV for ECR) as per results published in the British Journal of Cancer
  • 02 Jul 2018 Results published in the British Journal of Cancer
  • 09 Feb 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2009-013279-23).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top